Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Enlivex ( (ENLV) ) is now available.
On November 10, 2025, Enlivex Therapeutics Ltd. attempted to hold its Annual General Meeting of Shareholders but had to adjourn due to a lack of quorum. The meeting is rescheduled for November 17, 2025, with extended deadlines for shareholder voting, reflecting the company’s commitment to ensuring shareholder participation and governance compliance.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a company based in Israel, operating in the biotechnology industry. It focuses on developing innovative therapies for immune system modulation, aiming to address life-threatening diseases.
Average Trading Volume: 499,001
Technical Sentiment Signal: Sell
Current Market Cap: $23.86M
For an in-depth examination of ENLV stock, go to TipRanks’ Overview page.